TUSTIN, Calif., March 13, 2018 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate at two upcoming CDMO industry conferences. These include KNect365 Life Sciences’ BioProcess International West 2018, being held March 19-22, 2018 in San Francisco, CA, and DCAT Week 2018, being held March 19-22, 2018 in New York, NY.
Details of these activities are as follows:
KNect365 Life Sciences' BioProcess International West:
Avid will host corporate booth #415 showcasing the company’s comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services. Company representatives will provide a virtual tour of Avid’s 40,000 square foot state-of-the-art commercial biomanufacturing suite (Myford facility). The Myford facility is designed with cutting-edge, single-use equipment to accommodate a fully disposable biomanufacturing process. A wide range of innovative features are incorporated into the facility including monolithic modular clean rooms, dedicated support utilities for each key processing area, and the industry’s most advanced single-use production systems and flexible solutions. Uni-directional process flows separate personnel and materials and provide assurance that the design meets the most stringent regulatory requirements for commercial biologics API manufacturing.
DCAT Week:
Avid representatives will also be onsite at DCAT Week, an event hosted by the Drug, Chemical & Associated Technologies Association (DCAT). In addition to participating in related networking events, the company is hosting a table at the DCAT Annual Dinner on Thursday, March 22.
For additional details on these events, please visit: https://lifesciences.knect365.com/bpi-west/ and https://dcatweek.org/.
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com
Contacts: Kelly Pisarev Lord Avid Bioservices, Inc. (800) 987-8256 Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]


UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
Nintendo Shares Jump as Switch 2 Sales Boost Earnings
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
DeepSeek to Raise AI API Prices as Demand for New Models Surges 



